Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Texas › Dallas
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Dallas, TX keessatti
Qorannoo 52 Kansara Qara'a Non-Small Cell f Dallas fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- Texas Oncology - Dallas - Worth Street /ID# 278947, Dallas
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Namoota walitti qabaa jiraSadarkaa 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- UT Southwest Simmons Cancer Center, Dallas
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology - DFW ( Site 8103), Dallas
- UT Southwestern Medical Center ( Site 0190), Dallas
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #89, Dallas
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology Dallas, Dallas
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- fi 2 dabalataa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- fi 2 dabalataa
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- UT Southwestern Medical Center, Dallas
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Namoota walitti qabaa jiraSadarkaa 1/2
- Baylor, Scott and White Research Institute, Dallas
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 1
- UT Southwestern Medical Center at Dallas, Dallas
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology Sammons Cancer Center, Dallas
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Study Site, Dallas
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT - Dallas, Dallas
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Namoota walitti qabaa jiraSadarkaa 2/3
- Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Namoota walitti qabaa jiraQorannoo ilaalaa
- UT Southwestern Medical Center, Dallas
A Study of KK2269 in Adult Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas Southwestern Medical Center, Dallas
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Mary Crowley Cancer Research, Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Mary Crowley Cancer Research, Dallas
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- The University of Texas Southwestern Medical Center at Dallas, Dallas
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Namoota walitti qabaa jiraSadarkaa 1
- Ut Southwestern, Dallas
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology, Dallas
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Baylor Charles A. Sammons Cancer Center, Dallas
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Texas Oncology - DFW, Dallas
A Study of DM005 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute at Mary Crowley, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Mary Crowley Cancer Research, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- fi 2 dabalataa
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Texas Oncology - DFW, Dallas
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- University of Texas Southwestern Medical Center, Dallas
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Namoota walitti qabaa jiraSadarkaa 3
- Old Parkland Hospital Hematology Oncology Clinic, Dallas
- UT Southwestern Medical Center, Dallas
Study of XB010 in Subjects With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Baylor University Medical Center, Dallas
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Texas LLC - Dallas, Dallas
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UT Southwestern Simmons Cancer Center, Dallas
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Texas Southwestern Medical Center /ID# 251974, Dallas
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Namoota walitti qabaa jiraSadarkaa 1/2
- UT Southwestern Medical Center, Dallas
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Namoota walitti qabaa jiraSadarkaa 1/2
- Mary Crowley Cancer Research, Dallas
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Namoota walitti qabaa jiraSadarkaa 2
- UT Southwestern Medical Center, Dallas
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Texas Southwestern Medical Center, Dallas
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- University of Texas Southwestern Medical Center, Dallas
A Study of VET3-TGI in Patients With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Mary Crowley Cancer Research, Dallas
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Dallas, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Oncology - Dallas, Dallas
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Oncology Dallas, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Namoota walitti qabaa jiraSadarkaa 1
- Dren Investigational Site, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Dallas
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Baylor Scott and White Research Institute, Dallas
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Dallas keessatti
- Saree OljooQorannoo 55
- Kansara MetastatikiiQorannoo 42
- Cufama OnneeQorannoo 42
- Saree (Gosoota Hunda)Qorannoo 37
- Kansarii ProstateQorannoo 36
- Kansarii ColorectalQorannoo 33
- ObesityQorannoo 30
- Kansarii OvariiQorannoo 28
- Dhibee QaraQorannoo 27
- Dukkana BladderQorannoo 27
- Kansa EndometiriyaaliiQorannoo 24
- Kansara Harkaa (Karsinomaa Seli Renal)Qorannoo 23
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.